A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Small-cell Lung Cancer · Neuroendocrine Carcinomas · Solid Tumor Show to Express DLL3
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 262 (planned)
- Started
- Oct 14, 2025
- Main results expected
- Jul 2029
- Fully finished
- Jul 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1A: Safety and Tolerability of IDE849 (Monotherapy)
Measured over: approximately 4 years total study duration
Part 1B: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161
Measured over: approximately 4 years total study duration
Part 2: Safety and Tolerability of IDE849 (Monotherapy Dose Expansion)
Measured over: approximately 4 years total study duration
Part 2: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161 or durvalumab + carboplatin (Dose Expansion)
Measured over: approximately 4 years total study duration
Part 2: Objective Response Rate (ORR) and Investigator Assessment of IDE849 ORR per RECIST 1.1
Measured over: approximately 4 years total study duration
Part 2: Duration of Response (DOR) and Investigator Assessment of IDE849 DOR per RECIST 1.1
Measured over: approximately 4 years total study duration
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07174583 · record last updated 2026-07-09 · checked 2026-11-09 15:36 UTC